Peptides and combination of peptides for use in immunotherapy against cancers
Inventors
Weinschenk, Toni • Schoor, Oliver • MAHR, Andrea
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present description relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer. The present description further relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Core Innovation
The invention relates to cancer immunotherapy that elicits an immune response in a patient with cancer by administering a composition of activated T cells. The activated T cells selectively recognize cancer cells that present a peptide consisting of the amino acid sequence KIQEILTQV (SEQ ID NO: 1). The disclosed peptide is presented in the context of major histocompatibility complex (MHC) recognition, including MHC class I (HLA) and MHC class II binding forms described in the document.
The document emphasizes peptide-based recognition of tumor-associated peptide epitopes and includes a preferred HLA-binding peptide with KIQEILTQV (SEQ ID NO: 1), together with peptide variants and elongated class I/class II binding forms. It further includes forms and variants for generating tumor-reactive T-cell receptor (TCR) proteins and related immunotherapeutic modalities, including soluble TCR and T-cell associated therapeutic formats.
The disclosed approach is applied to a set of cancer types in which tumor cells present the specified peptide epitope. The document reports supporting results for peptide presentation associated with HLA-A*02:01, including predicted and observed presentation, and describes immunogenicity and functional T-cell activity for specific TCRs measured by IFN-γ release and EC50 values in HLA/peptide-specific assays.
Claims Coverage
The identified independent claim contains a single inventive concept: administering activated T cells that selectively recognize cancer cells presenting a specific peptide epitope, with the cancer restricted to a defined set of cancer types (one principal inventive feature).
Administering activated T cells recognizing cancer-presented KIQEILTQV (SEQ ID NO: 1) peptide
Administering to a patient a composition comprising a population of activated T cells that selectively recognize the cancer cells that present a peptide consisting of the amino acid sequence of KIQEILTQV (SEQ ID NO: 1).
Overall claim coverage centers on using activated T cells with selectivity defined by presentation of the KIQEILTQV (SEQ ID NO: 1) peptide epitope, limited to a specified group of cancer types.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?